2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
08/16/18Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process
CAMBRIDGE, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) completed the NIH protocol registration process for EDIT-101. The NIH determined a public meeting is not necessary, and the RAC will not be convened to review this clinical trial. EDIT-101 is Editas Medicine’s experimental CRISPR genome editing medicine for the treatment of... 
 Printer Friendly Version
08/06/18Editas Medicine Announces Second Quarter 2018 Results and Update
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101 Investigational New Drug (IND) application in October 2018 Strong balance sheet to advance Company through multiple value inflection points CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today reported financial results f... 
 Printer Friendly Version
08/06/18Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
Reinforces both Allergan’s and Editas’ continued commitment to developing innovative treatments for unmet needs in eye care Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceut... 
 Printer Friendly Version
07/30/18Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, August 6, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the second quarter of 2018. To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 4379216. A live webcast of the presentation will be available on the Investors... 
 Printer Friendly Version
06/13/18Editas Medicine to Participate in The JMP Securities Life Sciences Conference
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences Conference in New York on Wednesday, June 20, 2018.  Details of the panel are as follows: Panel: Gene Editing – From Science to Reality Date: Wednesday, June 20, 2018 Time: 8:00 a.m. Location: St. Regis Hotel, New York                           About Ed... 
 Printer Friendly Version
05/18/18Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates
Presentation at the Annual Meeting of the American Society of Gene & Cell Therapy CAMBRIDGE, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating that EDIT-101 was well-tolerated when administered to non-human primates (NHP) via subretinal injection. EDIT-101 is the Company’s experimental medicine for the treatment of Leber Congenital Amaurosis type 10 (LCA10).  The Co... 
 Printer Friendly Version
05/08/18Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018, at 8 a.m. PT (11:00 a.m. ET) in Las Vegas, Nevada. A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will... 
 Printer Friendly Version
05/03/18Editas Medicine Announces First Quarter 2018 Results and Update
Expanded Celgene collaboration to drive lead oncology program in solid tumors Strengthened Board of Directors with addition of James C. Mullen and Jessica Hopfield, Ph.D. Cash, cash equivalents, and marketable securities of $359 million as of March 31, 2018 CAMBRIDGE, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the first quarter ended March 31, 2018, and provided an update on recent achie... 
 Printer Friendly Version
04/30/18Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting
Oral presentation of tolerability and immunogenicity data from a study of EDIT-101 following subretinal injection in non-human primates CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that 10 scientific abstracts, including three from research collaborations, have been accepted for presentation at the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). The meeting will take ... 
 Printer Friendly Version
04/26/18Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 3, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of 2018. To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 6079429. A live webcast of the presentation will be available on the Investors ... 
 Printer Friendly Version
03/28/18Editas Medicine Names James C. Mullen as Chairman of the Board of Directors
CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of James C. Mullen as Chairman of the Board of Directors, effective immediately. Mr. Mullen has more than 30 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, Mr. Mullen served as Chief Executive Officer of Patheon N.V., a leading global provider of pharmaceutical developme... 
 Printer Friendly Version
03/06/18Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing Expecting at least five clinical-stage programs by end of 2022 as part of EM22 five-year goals Year-end cash, cash equivalents, and marketable securities of $329 million expected to fund business for at least 24 months CAMBRIDGE, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results ... 
 Printer Friendly Version
02/28/18Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the Company has joined forces with 30 million Americans and health care advocates around the world for Rare Disease Day® today. Rare Disease Day is an annual awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people face. “The team at Editas Medicine has the bold vision to unlock the p... 
 Printer Friendly Version
02/27/18Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 6th, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2017. To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 2449529. A live webcast of the presentation will be available ... 
 Printer Friendly Version
02/16/18Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors
CAMBRIDGE, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield will also serve on the Audit Committee of the Board. Dr. Hopfield is a scientist and business leader with more than two decades of experience in the medical and healthcare fields. She is currently the Chairperson of the Board of Trustees of the Josl... 
 Printer Friendly Version
02/08/18Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor conferences. Details are as follows: BIO CEO & Investor Conference Date:   Monday, February 12, 2018 Forum:   Presentation Time:   1:30 p.m. ET Location:   New York       ... 
 Printer Friendly Version
01/08/18Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference
By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials Announces first acquisition with purchase of certain assets from i2 Pharmaceuticals and its affiliates, further strengthening Editas’ guide RNA chemistry capabilities and intellectual property Provides updates on advancements in ocular and engineered cell medicine programs CAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NE... 
 Printer Friendly Version
01/03/18Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018, at 8:30 a.m. PT (11:30 a.m. ET) in San Francisco, CA. A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas... 
 Printer Friendly Version
Print Page    E-mail Page    RSS    E-mail Alerts